PMID- 10636127 OWN - NLM STAT- MEDLINE DCOM- 20000127 LR - 20190514 IS - 0028-3878 (Print) IS - 0028-3878 (Linking) VI - 54 IP - 1 DP - 2000 Jan 11 TI - Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. PG - 65-71 AB - OBJECTIVE: To investigate the role of matrix metalloproteinases (MMPs) in the pathogenesis of inflammatory myopathies and the amyloid formation in sporadic inclusion body myositis (s-IBM). BACKGROUND: MMPs comprise a family of calcium-dependent zinc endoproteinases induced by cytokines and secreted by inflammatory cells. They enhance T-cell migration or adhesion and degrade components of the extracellular matrix proteins. Some MMPs also have been implicated in the formation of beta-amyloid. METHODS: We examined the expression of MMPs with single and double immunocytochemistry using antibodies against MMP-2, MMP-3, MMP-7, MMP-9, major histocompatibility complex (MHC) class I, CD8+ cells, macrophage, and beta-amyloid precursor protein (beta-APP) on serial muscle biopsy sections from patients with s-IBM, polymyositis (PM), dermatomyositis (DM), and disease control specimens. The enzyme activity of MMPs was measured by gelatin substrate zymography. RESULTS: Only the gelatinases, MMP-9 and MMP-2, were expressed in the muscle. In s-IBM and PM, but not the control specimens, MMP-9 and MMP-2 immunostained the non-necrotic and MHC class-I-expressing muscle fibers, and MMP-9, but not MMP-2, immunostained the autoinvasive CD8+ cytotoxic T cells. Zymography in muscle homogenates confirmed the increased MMP-2 and MMP-9 enzymatic activity. MMP-2, but not MMP-9, immunostained the rimmed vacuoles in s-IBM and colocalized with beta-APP, suggesting a possible involvement with the amyloid deposits. CONCLUSIONS: Because collagen IV is prominent on the muscle membrane, the overexpression of matrix metalloproteinases (MMPs) 2 and 9 on the non-necrotic muscle fibers in polymyositis (PM) and sporadic inclusion body myositis (s-IBM) may facilitate lymphocyte adhesion and enhance T-cell-mediated cytotoxicity by degrading extracellular matrix proteins. The findings may have practical implications in considering therapeutic trials with MMP inhibitors in patients with PM and s-IBM. FAU - Choi, Y C AU - Choi YC AD - Neuromuscular Disease Section, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD 20892-1382, USA. FAU - Dalakas, M C AU - Dalakas MC LA - eng PT - Journal Article PL - United States TA - Neurology JT - Neurology JID - 0401060 RN - 0 (Amyloid beta-Protein Precursor) RN - 0 (Histocompatibility Antigens Class I) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Amyloid beta-Protein Precursor/metabolism MH - CD8-Positive T-Lymphocytes/enzymology MH - Dermatomyositis/*enzymology/metabolism/pathology MH - Histocompatibility Antigens Class I/metabolism MH - Humans MH - Immunohistochemistry MH - Matrix Metalloproteinase 2/*metabolism MH - Matrix Metalloproteinase 9/*metabolism MH - Muscle Fibers, Skeletal/metabolism MH - Muscle, Skeletal/*enzymology/pathology MH - Myositis, Inclusion Body/*enzymology/metabolism/pathology MH - Polymyositis/*enzymology/metabolism/pathology EDAT- 2000/01/15 00:00 MHDA- 2000/01/15 00:01 CRDT- 2000/01/15 00:00 PHST- 2000/01/15 00:00 [pubmed] PHST- 2000/01/15 00:01 [medline] PHST- 2000/01/15 00:00 [entrez] AID - 10.1212/wnl.54.1.65 [doi] PST - ppublish SO - Neurology. 2000 Jan 11;54(1):65-71. doi: 10.1212/wnl.54.1.65.